North America Acute Pancreatitis Market Forecast to 2030 – Regional Analysis – by Offerings (Medications, Diagnosis, and Others), Causes (Gallstones, Alcoholism, Genetic Disorders, Infection, and Others), and End User (Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers, and Others)
The North America acute pancreatitis market was valued at US$ 3,209.63 million in 2022 and is expected to reach US$ 5,000.71 million by 2030; it is estimated to grow at a CAGR of 5.7% from 2022 to 2030.
Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis Fuels the North America Acute Pancreatitis Market
Pancreatic cancer is the fourth leading cause of cancer-related mortality in Western countries. According to the American Cancer Society, Cancer Facts & Figures 2022, the mortality rate of pancreatic cancer is predicted to be the second highest among all cancer-led mortality rates in the US by 2030. It is more likely to progress if not detected early when the tumor is resectable. According to an article published in the National Library of Medicine in 2021, only ~15% of pancreatic tumors are resectable at diagnosis, limiting five-year survival to 8%. However, the lack of early symptoms results in poor diagnosis and low resectability of these tumors. Acute pancreatitis may cause pancreatic cancer as it is an early symptom of pancreatic cancer, nearly 1% of acute pancreatitis admissions result in pancreatic cancer diagnoses. It takes several months for these patients to be diagnosed with pancreatic cancer after acute pancreatitis is diagnosed, but some suffer longer diagnostic delays due to initial misdiagnosis, which may hinder their recovery. Recurrent occurrence of acute pancreatitis leads to chronic pancreatitis, which may further increase the risk of pancreatic cancer.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, acute pancreatitis leads to ~275,000 hospital admissions each year, and this number has been increasing in the US. ~35–40% of acute pancreatitis cases in the US are due to gallstones, while alcohol consumption is the cause of 30% of cases. Pancreatitis is usually mild in 80% of patients who are admitted, and most can be discharged within a few days of their hospitalization. Acute pancreatitis is associated with a mortality rate of ~2% and has a relapse rate between 0.6% and 5.6%. Alcohol-related pancreatitis has the highest rate of relapse. According to an article published in Lancet Gastroenterology Hepatology in 2022, the global pooled incidence of acute pancreatitis is 34 cases per 100,000 per year. North America has 58.2 cases per 100,000 people per year (the US has 58.2 cases per 100,000 people per year) while Europe has 24.7 and 15.0 cases per 100,000 people in Sweden and Denmark, respectively.
Acute pancreatitis, which causes the release of digestive enzymes into the pancreatic interstitial space instead of the pancreatic duct lumen, could be an early indicator of pancreatic cancer due to tumor obstruction of the pancreatic duct. Acute pancreatitis is a painful condition, so patients seek medical care sooner, which could lead to an early cancer diagnosis. Therefore, rising cases of pancreatic cancer due to acute pancreatitis boosts the growth of the North America acute pancreatitis market.
North America Acute Pancreatitis Market Overview
The North America acute pancreatitis market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period. the North America acute pancreatitis market in North America is expected to grow due to the increasing burden of acute pancreatitis due to increase in cases of gallstones and excessive consumption of alcohol. Also, with an increase in technological advancement in healthcare facilities, the market in North America is expected to grow during the forecast period.
North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
North America Acute Pancreatitis Market Segmentation
The North America acute pancreatitis market is segmented offerings, causes, end user, and country.
Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the North America acute pancreatitis market is segmented into the US, Canada, and Mexico. The US dominated the North America acute pancreatitis market share in 2022.
Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the North America acute pancreatitis market.
Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis Fuels the North America Acute Pancreatitis Market
Pancreatic cancer is the fourth leading cause of cancer-related mortality in Western countries. According to the American Cancer Society, Cancer Facts & Figures 2022, the mortality rate of pancreatic cancer is predicted to be the second highest among all cancer-led mortality rates in the US by 2030. It is more likely to progress if not detected early when the tumor is resectable. According to an article published in the National Library of Medicine in 2021, only ~15% of pancreatic tumors are resectable at diagnosis, limiting five-year survival to 8%. However, the lack of early symptoms results in poor diagnosis and low resectability of these tumors. Acute pancreatitis may cause pancreatic cancer as it is an early symptom of pancreatic cancer, nearly 1% of acute pancreatitis admissions result in pancreatic cancer diagnoses. It takes several months for these patients to be diagnosed with pancreatic cancer after acute pancreatitis is diagnosed, but some suffer longer diagnostic delays due to initial misdiagnosis, which may hinder their recovery. Recurrent occurrence of acute pancreatitis leads to chronic pancreatitis, which may further increase the risk of pancreatic cancer.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, acute pancreatitis leads to ~275,000 hospital admissions each year, and this number has been increasing in the US. ~35–40% of acute pancreatitis cases in the US are due to gallstones, while alcohol consumption is the cause of 30% of cases. Pancreatitis is usually mild in 80% of patients who are admitted, and most can be discharged within a few days of their hospitalization. Acute pancreatitis is associated with a mortality rate of ~2% and has a relapse rate between 0.6% and 5.6%. Alcohol-related pancreatitis has the highest rate of relapse. According to an article published in Lancet Gastroenterology Hepatology in 2022, the global pooled incidence of acute pancreatitis is 34 cases per 100,000 per year. North America has 58.2 cases per 100,000 people per year (the US has 58.2 cases per 100,000 people per year) while Europe has 24.7 and 15.0 cases per 100,000 people in Sweden and Denmark, respectively.
Acute pancreatitis, which causes the release of digestive enzymes into the pancreatic interstitial space instead of the pancreatic duct lumen, could be an early indicator of pancreatic cancer due to tumor obstruction of the pancreatic duct. Acute pancreatitis is a painful condition, so patients seek medical care sooner, which could lead to an early cancer diagnosis. Therefore, rising cases of pancreatic cancer due to acute pancreatitis boosts the growth of the North America acute pancreatitis market.
North America Acute Pancreatitis Market Overview
The North America acute pancreatitis market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period. the North America acute pancreatitis market in North America is expected to grow due to the increasing burden of acute pancreatitis due to increase in cases of gallstones and excessive consumption of alcohol. Also, with an increase in technological advancement in healthcare facilities, the market in North America is expected to grow during the forecast period.
North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
North America Acute Pancreatitis Market Segmentation
The North America acute pancreatitis market is segmented offerings, causes, end user, and country.
Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the North America acute pancreatitis market is segmented into the US, Canada, and Mexico. The US dominated the North America acute pancreatitis market share in 2022.
Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the North America acute pancreatitis market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 North America Acute Pancreatitis Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA ACUTE PANCREATITIS MARKET LANDSCAPE
4.1 Overview
5. NORTH AMERICA ACUTE PANCREATITIS MARKET - KEY INDUSTRY DYNAMICS
5.1 Key Market Drivers
5.1.1 Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis
5.1.2 Rising Incidence of Diabetes Following Acute Pancreatitis
5.2 Key Market Restraints
5.2.1 Side Effects of Pancreatitis and Pancreatic Cancer Treatments
5.3 Key Market Opportunities
5.3.1 Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis
5.4 Future Trends
5.4.1 Advancements in Specific Acute Pancreatitis Treatments
5.5 Impact Analysis:
6. ACUTE PANCREATITIS MARKET – NORTH AMERICA MARKET ANALYSIS
6.1 North America Acute Pancreatitis Market Revenue (US$ Mn), 2022 – 2030
7. NORTH AMERICA ACUTE PANCREATITIS MARKET – REVENUE AND FORECAST TO 2030 – BY OFFERINGS
7.1 Overview
7.2 North America Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
7.3 Medications
7.3.1 Overview
7.3.2 Medications: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 North America Acute Pancreatitis Market, by Medications, 2020–2030 (US$ Million)
7.4 Diagnosis
7.4.1 Overview
7.4.2 Diagnosis: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 North America Acute Pancreatitis Market, by Diagnosis, 2020–2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8. NORTH AMERICA ACUTE PANCREATITIS MARKET – REVENUE AND FORECAST TO 2030 – BY CAUSES
8.1 Overview
8.2 North America Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
8.3 Gallstones
8.3.1 Overview
8.3.2 Gallstones: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Alcoholism
8.4.1 Overview
8.4.2 Alcoholism: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Genetic Disorders
8.5.1 Overview
8.5.2 Genetic Disorders: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Infections
8.6.1 Overview
8.6.2 Infections: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9. NORTH AMERICA ACUTE PANCREATITIS MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
9.1 Overview
9.2 North America Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Ambulatory Surgical Centers
9.5.1 Overview
9.5.2 Ambulatory Surgical Centers: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
10. NORTH AMERICA ACUTE PANCREATITIS MARKET - COUNTRY ANALYSIS
10.1 Overview
10.1.1.1 North America Acute Pancreatitis Market, by Country
10.1.1.2 US
10.1.1.2.1 Overview
10.1.1.2.2 US: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.3 US: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.2.3.1 US: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.2.3.2 US: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.2.4 US: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.2.5 US: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
10.1.1.3 Canada
10.1.1.3.1 Overview
10.1.1.3.2 Canada: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.3 Canada: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.3.3.1 Canada: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.3.3.2 Canada: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.3.4 Canada: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.3.5 Canada: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
10.1.1.4 Mexico
10.1.1.4.1 Overview
10.1.1.4.2 Mexico: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.3 Mexico: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.4.3.1 Mexico: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.4.3.2 Mexico: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.4.4 Mexico: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.4.5 Mexico: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
11. NORTH AMERICA ACUTE PANCREATITIS MARKET–INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in the North America Acute Pancreatitis Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 GE HealthCare Technologies Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Samsung Healthcare
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Koninklijke Philips NV
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Baxter International Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Dynavax Technologies Corp
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Medtronic Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Boston Scientific Corp
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Fresenius Kabi AG
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. APPENDIX
13.1 About Us
13.2 Glossary of Terms
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 North America Acute Pancreatitis Market, by Country (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. NORTH AMERICA ACUTE PANCREATITIS MARKET LANDSCAPE
4.1 Overview
5. NORTH AMERICA ACUTE PANCREATITIS MARKET - KEY INDUSTRY DYNAMICS
5.1 Key Market Drivers
5.1.1 Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis
5.1.2 Rising Incidence of Diabetes Following Acute Pancreatitis
5.2 Key Market Restraints
5.2.1 Side Effects of Pancreatitis and Pancreatic Cancer Treatments
5.3 Key Market Opportunities
5.3.1 Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis
5.4 Future Trends
5.4.1 Advancements in Specific Acute Pancreatitis Treatments
5.5 Impact Analysis:
6. ACUTE PANCREATITIS MARKET – NORTH AMERICA MARKET ANALYSIS
6.1 North America Acute Pancreatitis Market Revenue (US$ Mn), 2022 – 2030
7. NORTH AMERICA ACUTE PANCREATITIS MARKET – REVENUE AND FORECAST TO 2030 – BY OFFERINGS
7.1 Overview
7.2 North America Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
7.3 Medications
7.3.1 Overview
7.3.2 Medications: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 North America Acute Pancreatitis Market, by Medications, 2020–2030 (US$ Million)
7.4 Diagnosis
7.4.1 Overview
7.4.2 Diagnosis: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 North America Acute Pancreatitis Market, by Diagnosis, 2020–2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8. NORTH AMERICA ACUTE PANCREATITIS MARKET – REVENUE AND FORECAST TO 2030 – BY CAUSES
8.1 Overview
8.2 North America Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
8.3 Gallstones
8.3.1 Overview
8.3.2 Gallstones: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Alcoholism
8.4.1 Overview
8.4.2 Alcoholism: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Genetic Disorders
8.5.1 Overview
8.5.2 Genetic Disorders: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Infections
8.6.1 Overview
8.6.2 Infections: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9. NORTH AMERICA ACUTE PANCREATITIS MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
9.1 Overview
9.2 North America Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Ambulatory Surgical Centers
9.5.1 Overview
9.5.2 Ambulatory Surgical Centers: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: North America Acute Pancreatitis Market – Revenue and Forecast to 2030 (US$ Million)
10. NORTH AMERICA ACUTE PANCREATITIS MARKET - COUNTRY ANALYSIS
10.1 Overview
10.1.1.1 North America Acute Pancreatitis Market, by Country
10.1.1.2 US
10.1.1.2.1 Overview
10.1.1.2.2 US: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.3 US: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.2.3.1 US: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.2.3.2 US: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.2.4 US: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.2.5 US: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
10.1.1.3 Canada
10.1.1.3.1 Overview
10.1.1.3.2 Canada: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.3 Canada: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.3.3.1 Canada: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.3.3.2 Canada: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.3.4 Canada: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.3.5 Canada: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
10.1.1.4 Mexico
10.1.1.4.1 Overview
10.1.1.4.2 Mexico: North America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.3 Mexico: North America Acute Pancreatitis Market, by Offerings, 2020–2030 (US$ Million)
10.1.1.4.3.1 Mexico: North America Acute Pancreatitis Market, For Medications by Offerings, 2020–2030 (US$ Million)
10.1.1.4.3.2 Mexico: North America Acute Pancreatitis Market, For Diagnosis by Offerings, 2020–2030 (US$ Million)
10.1.1.4.4 Mexico: North America Acute Pancreatitis Market, by Causes, 2020–2030 (US$ Million)
10.1.1.4.5 Mexico: North America Acute Pancreatitis Market, by End User, 2020–2030 (US$ Million)
11. NORTH AMERICA ACUTE PANCREATITIS MARKET–INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in the North America Acute Pancreatitis Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 GE HealthCare Technologies Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Samsung Healthcare
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Koninklijke Philips NV
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Baxter International Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Dynavax Technologies Corp
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Medtronic Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Boston Scientific Corp
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Fresenius Kabi AG
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. APPENDIX
13.1 About Us
13.2 Glossary of Terms
